Effect of inclisiran, the small-interfering RNA against proprotein convertase subtilisin/kexin type 9, on platelets, immune cells, and immunological biomarkers: a pre-specified analysis from ORION-1
The DOI matches its Crossref record; 18 of the 19 references it cites were found in a registry or an index.
Abstract
Aims: Small-interfering RNA (siRNA)-based targeting of proprotein convertase subtilisin/kexin type 9 (PCSK9) represents a novel therapeutic approach that may provide a convenient, infrequent, and safe dosing schedule to robustly lower low-density lipoprotein cholesterol (LDL-C). Given the long duration of action, however, establishing safety in particular with respect to immunogenicity is of paramount importance. In earlier clinical studies of other RNA-targeted treatment approaches (antisense oligonucleotide therapy) immunological and haematological adverse effects, in particular thrombocytopenia and pro-inflammatory effects, have been reported. Here, we present the pre-specified safety analysis from ORION-1 evaluating platelets, immune cells, immunological markers, antidrug antibodies, and clinical immunogenicity adverse events (AEs) under PCSK9 siRNA treatment with inclisiran. Methods and results: The pre-specified safety analysis from ORION-1 was performed in six different inclisiran dosing regimens in patients at high risk of cardiovascular disease with elevated LDL-C levels. Patients received either a single dose (SD: 200 mg, n = 60; 300 mg, n = 62 or 500 mg, n = 66) or double-dose starting regimen (DD: 100 mg, n = 62; 200 mg, n = 63; or 300 mg, n = 61 on days 1 and 90) of inclisiran or placebo (SD: n = 65; DD: n = 62). The effects of inclisiran on haematological parameters including platelet counts, lymphocytes, and monocytes as well as on the immune markers interleukin 6 (IL-6) and tumour necrosis factor-α (TNF-α) were examined after 180 days. Immunogenicity was further evaluated by analysis of anti-drug-antibodies (ADAs) towards inclisiran in 6068 study samples and by careful analysis of immunogenicity AEs as part of the pharmacovigilance strategy. At day 180, no significant alterations of platelet counts were observed in any of the dosing groups (change from baseline, SD: 200 mg: 0.8%; 300 mg: −0.5%; 500 mg: −1.8%; DD: 100 mg: 1.3%; 200 mg: −0.5%; 300 mg: 1.0%; no significant difference for any group as compared with placebo). No significant effects on other immune cells, including leucocytes, monocytes, or neutrophils were detected. Notably, no significant increase of inflammatory biomarkers (IL-6 or TNF-α) with either the SD or DD regimen became evident. There was no evidence for immunogenicity based on ADA level analysis and careful review of clinical immunogenicity AEs in none of the treatment regimens. Conclusion: In this pre-specified safety analysis of ORION-1 for the siRNA therapeutic inclisiran, no adverse effects on measures of inflammation or immune activation nor adverse effects on platelets or clinical immunogenicity AEs were observed over at least 6-month treatment. These safety findings in the largest analysis of an RNAi study in humans to date provide strong reassurance about the safety of inclisiran and the potential of cardiovascular RNA-targeted therapies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In contrast to the other PCSK9 inhibitors, inclisiran does not induce the expression of auto-antibodies according to results from the ORION-1 trial [142].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [142]
In the citing paper
“A sub study of ORION-1 examined immunologic safety by measuring pro-inflammatory cytokines and leukocytes as well as complement activation and found no systemic inflammation in inclisiran-treated patients [52].”
In the citing paper
“The absence of detected anti-drug antibodies in the siRNA platform confirms its low immunogenic nature [52].”
Citations
Cites
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707914 · Cited by 9,482
Self-citationMechanisms of gene silencing by double-stranded RNA
Meister, G., & Tuschl, T. (2004) · Nature · doi:10.1038/nature02873 · Cited by 2,539
Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs
Soutschek, J., Akinc, A., Bramlage, B., Charisse, K., Constien, R., Donoghue, M., Elbashir, S., Geick, A., Hadwiger, P., Harborth, J., et al. (2004) · Nature · doi:10.1038/nature03121 · Cited by 2,183
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
Benson, M. D., Waddington-Cruz, M., Berk, J. L., Polydefkis, M., Dyck, P. J., Wang, A. K., Planté-Bordeneuve, V., Barroso, F. A., Merlini, G., Obici, L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716793 · Cited by 1,452
Hornung, V., Guenthner-Biller, M., Bourquin, C., Ablasser, A., Schlee, M., Uematsu, S., Noronha, A., Manoharan, M., Akira, S., de Fougerolles, A., et al. (2005) · Nature Medicine · doi:10.1038/nm1191 · Cited by 1,232
Nair, J. K., Willoughby, J. L. S., Chan, A., Charisse, K., Alam, M. R., Wang, Q., Hoekstra, M., Kandasamy, P., Kel’in, A. V., Milstein, S., et al. (2014) · Journal of the American Chemical Society · doi:10.1021/ja505986a · Cited by 1,141
Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol
Ray, K. K., Landmesser, U., Leiter, L. A., Kallend, D., Dufour, R., Karakas, M., Hall, T., Troquay, R. P. T., Turner, T., Visseren, F. L. J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615758 · Cited by 992
Self-citationTherapeutic siRNA silencing in inflammatory monocytes in mice
Leuschner, F., Dutta, P., Gorbatov, R., Novobrantseva, T. I., Donahoe, J. S., Courties, G., Lee, K. M., Kim, J. I., Markmann, J. F., Marinelli, B., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1989 · Cited by 839
A highly durable RNAi therapeutic inhibitor of PCSK9
Fitzgerald, K., White, S., Borodovsky, A., Bettencourt, B. R., Strahs, A., Clausen, V., Wijngaard, P., Horton, J. D., Taubel, J., Brooks, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609243 · Cited by 768
Self-citationSioud, M. (2005) · Journal of Molecular Biology · doi:10.1016/j.jmb.2005.03.013 · Cited by 418
Cited by
Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention
Michaeli, D. T., Michaeli, J. C., Albers, S., Boch, T., & Michaeli, T. (2023) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-023-00594-5 · Cited by 109
“In contrast to the other PCSK9 inhibitors, inclisiran does not induce the expression of autoantibodies according to results from the ORION-1 trial [142].”
ResultClinical approach to the inflammatory etiology of cardiovascular diseases
Ruscica, M., Corsini, A., Ferri, N., Banach, M., & Sirtori, C. R. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104916 · Cited by 89
Merćep, I., Friščić, N., Strikić, D., & Reiner, Ž. (2022) · Cardiovascular Therapeutics · doi:10.1155/2022/8129513 · Cited by 85
“In the ORION-1 trial, the overall occurrence of adverse effects was 76% in both placebo and inclisiran arms, but severe adverse effects were observed in only 8% in the placebo group and 11% in the inclisiran group of patients [21, 26].”
BackgroundAngiotensinogen Suppression: A New Tool to Treat Cardiovascular and Renal Disease
Cruz‐López, E. O., Ye, D., Wu, C., Lu, H. S., Uijl, E., Colafella, K. M. M., & Danser, A. H. J. (2022) · Hypertension · doi:10.1161/hypertensionaha.122.18731 · Cited by 78
“78 Since this siRNA relies on the same GalNac principle, at present the safety profile of such drugs seems excellent.”
Emerging Non-statin Treatment Options for Lowering Low-Density Lipoprotein Cholesterol
Bardolia, C., Amin, N. S., & Turgeon, J. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.789931 · Cited by 74
PCSK9: A Multi-Faceted Protein That Is Involved in Cardiovascular Biology
Sundararaman, S. S., Döring, Y., & van der Vorst, E. P. C. (2021) · Biomedicines · doi:10.3390/biomedicines9070793 · Cited by 67
Beyond statins: New pharmacological targets to decrease LDL-cholesterol and cardiovascular events
Raschi, E., Casula, M., Cicero, A. F. G., Corsini, A., Borghi, C., & Catapano, A. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108507 · Cited by 59
Domingo, E., Marqués, P., Francisco, V., Piqueras, L., & Sanz, M. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107058 · Cited by 73
New Pharmacological Approaches to Target PCSK9
Catapano, A. L., Pirillo, A., & Norata, G. D. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00847-7 · Cited by 66
Inclisiran: a novel agent for lowering apolipoprotein B–containing lipoproteins
Warden, B. A., & Duell, P. B. (2021) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001053 · Cited by 62
Inclisiran: A Review in Hypercholesterolemia
Frampton, J. E. (2023) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-023-00568-7 · Cited by 61
“In line with data from the phase II ORION-1 study [21, 32] (Sect.”
ResultCurrent Options and Future Perspectives in the Treatment of Dyslipidemia
Muscoli, S., Ifrim, M., Russo, M., Candido, F., Sanseviero, A., Milite, M., Luozzo, M. D., Marchei, M., & Sangiorgi, G. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11164716 · Cited by 56
“ORION-8 is an ongoing study, evaluating the long-term efficacy and safety of inclisiran in patients with ASCVD, HeFH, or HoFH [45].”
BackgroundNishikido, T. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01752-4 · Cited by 46
“Furthermore, in the prespecified analysis of the ORION-1 trial, there was no evidence of significant increase in the levels of inflammatory biomarkers, such as interleukin-6 or tumor necrosis factor-α, or relevant formation of antidrug antibodies leading to a possible loss of function as illustrated with the anti- PCS…”
BackgroundSinning, D., & Landmesser, U. (2020) · Current Cardiology Reports · doi:10.1007/s11886-020-01427-6 · Cited by 44
Self-citationInclisiran—Safety and Effectiveness of Small Interfering RNA in Inhibition of PCSK-9
Wołowiec, Ł., Osiak, J., Wołowiec, A., Wijata, A., Grześk, E., Kozakiewicz, M., Banach, J., Nowaczyk, A., Nowaczyk, J., & Grześk, G. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020323 · Cited by 43
“A significant reduction in LDL-C was noted in all FH genotypes, with a similar frequency of serious adverse events in both groups [99].”
BackgroundResultPCSK9 in Myocardial Infarction and Cardioprotection: Importance of Lipid Metabolism and Inflammation
Andreadou, I., Tsoumani, M. E., Vilahur, G., Ikonomidis, I., Badimón, L., Varga, Z. V., Ferdinandy, P., & Schulz, R. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.602497 · Cited by 39
“Inclisiran, a long acting synthetic siRNA that targets hepatic PCSK9 synthesis, produces similar reductions in LDL-C as PCSK9 monoclonal antibodies (Board et al., 2020; Landmesser et al., 2020).”
BackgroundSmall interfering ribonucleic acid for cholesterol lowering – Inclisiran
Soffer, D. E., Stoekenbroek, R. M., & Plakogiannis, R. (2022) · Journal of clinical lipidology · doi:10.1016/j.jacl.2022.06.009 · Cited by 40
Self-citationCounteracting Angiotensinogen Small-Interfering RNA-Mediated Antihypertensive Effects With REVERSIR
Ye, D., Cruz‐López, E. O., van Veghel, R., Garrelds, I. M., Kasper, A., Wassarman, K., Tu, H.-C., Zlatev, I., & Danser, A. H. J. (2024) · Hypertension · doi:10.1161/hypertensionaha.124.22878 · Cited by 36
Cicero, A. F. G., Fogacci, F., Zambon, A., Toth, P. P., & Borghi, C. (2022) · American Heart Journal Plus: Cardiology Research and Practice · doi:10.1016/j.ahjo.2022.100127 · Cited by 34
“However, a recent publication has clearly highlighted that inclisiran did not exert any significant effect on immune cells (including leucocytes, monocytes, and neutrophils) and inflammatory biomarkers such as interleukin 6 (IL-6) and tumor necrosis factor alpha (TNF-α ) [44].”
BackgroundRNA Silencing in the Management of Dyslipidemias
Henney, N. C., Banach, M., & Penson, P. E. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00968-7 · Cited by 32
Inclisiran: A First-in-Class siRNA Therapy for Lowering Low-Density Lipoprotein Cholesterol
Samuel, E., Watford, M., Egolum, U. O., Ombengi, D., Ling, H., & Cates, D. W. (2022) · Annals of Pharmacotherapy · doi:10.1177/10600280221105169 · Cited by 34
Clinical Implications and Outcomes of the Orion Phase Iii Trials
Brandts, J., & Ray, K. K. (2020) · Future Cardiology · doi:10.2217/fca-2020-0150 · Cited by 31
Self-citationEfficacy, Safety, and Pharmacokinetics of Inclisiran in Japanese Patients: Results from ORION-15
Yamashita, S., Kiyosue, A., Maheux, P., Mena-Madrazo, J., Lesogor, A., Shao, Q., Tamaki, Y., Nakamura, H., Akahori, M., & Kajinami, K. (2024) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.64454 · Cited by 26
Lipid-Lowering Therapy after Acute Coronary Syndrome
Pogran, E., Burger, A. L., Zweiker, D., Kaufmann, C. C., Muthspiel, M., Rega‐Kaun, G., Wenkstetten-Holub, A., Wojta, J., Drexel, H., & Huber, K. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13072043 · Cited by 29
“Inclisiran, a siRNA-based PCSK9 inhibitor, however, has not exhibited any significant effects on platelets [75].”
BackgroundPleiotropic Effects of PCSK9: Focus on Thrombosis and Haemostasis
Puccini, M., Landmesser, U., & Rauch, U. (2022) · Metabolites · doi:10.3390/metabo12030226 · Cited by 27
“Inclisiran, a small interfering RNA-based PSCK9, has not shown any effect on platelets thus far [91].”
BackgroundSelf-citationYe, D., Cruz‐López, E. O., Tu, H.-C., Zlatev, I., & Danser, A. H. J. (2023) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.123.319897 · Cited by 26
Novel RNAi-Based Therapies for Atherosclerosis
Ruotsalainen, A., Mäkinen, P. I., & Ylä‐Herttuala, S. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00938-z · Cited by 27
Costanzo, A. D., Indolfi, C., Sorrentino, S., Esposito, G., & Spaccarotella, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411739 · Cited by 25
“The ORION-1 safety analysis showed that the drug did not cause immunogenicity towards platelets, immune system cells (lymphocytes and monocytes), and immune markers (IL-6 and TNF-α) [63].”
BackgroundThe Role of RNA-Targeted Therapeutics to Reduce ASCVD Risk: What Have We Learned Recently?
Miname, M. H., Rocha, V. Z., & Santos, R. D. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00936-1 · Cited by 26
The Interface of Therapeutics and Genomics in Cardiovascular Medicine
Magavern, E. F., Kaski, J. C., Turner, R. M., Janmohamed, A., Borry, P., & Pirmohamed, M. (2021) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07149-3 · Cited by 25
“Fortunately to date, the anti-PCSK9 siRNA therapeutic, inclisiran, has not shown haematological or immunological adverse events [128].”
BackgroundInclisiran: A New Pharmacological Approach for Hypercholesterolemia
Fusco, S. A. D., Maggioni, A. P., Bernelli, C., Perone, F., Marzo, V. D., Conte, E., Musella, F., Uccello, G., Luca, L. D., Gabrielli, D., et al. (2022) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2311375 · Cited by 26
Antiplatelet Effects of PCSK9 Inhibitors in Primary Hypercholesterolemia
Pęczek, P., Leśniewski, M., Mazurek, T., Szarpak, Ł., Filipiak, K. J., & Gąsecka, A. (2021) · Life · doi:10.3390/life11060466 · Cited by 23
The year in cardiovascular medicine 2021: dyslipidaemia
Tokgözoğlu, L. S., Orringer, C. E., Ginsberg, H. N., & Catapano, A. L. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab875 · Cited by 25
Adamidis, P. S., Pantazi, D., Moschonas, I. C., Liberopoulos, E. N., & Tselepis, A. D. (2024) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd11030072 · Cited by 22
“The pre-specified safety analysis from ORION-1 evaluating immune cells did not show any neutrophil alteration under PCSK9 siRNA treatment with inclisiran for 6 months [96].”
Metabolic disorders affecting the liver and heart: Therapeutic efficacy of miRNA-based therapies?
Sala, L. L., Carlini, V., Conte, C., Macas-Granizo, M. B., Afzalpour, E., Martín-Delgado, J., D’Anzeo, M., Pedretti, R. F. E., Naselli, A., Pontiroli, A. E., et al. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107083 · Cited by 18
Burger, A. L., Pogran, E., Muthspiel, M., Kaufmann, C. C., Jäger, B., & Huber, K. (2022) · Biomedicines · doi:10.3390/biomedicines10050970 · Cited by 17
“Although PCSK9 has a substantial impact in atherosclerotic disease progression and treatment with inclisiran was shown to significantly reduce LDL-C, the evidence on its potential effects on inflammation or thrombocyte function is limited so far [69].”
BackgroundInfluentialLazartigues, E. D., Llorens‐Cortés, C., & Danser, A. H. J. (2023) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2023.06.013 · Cited by 15
Tomlinson, B., Chow, E., Chan, P., & Lam, C. W. K. (2021) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2021.2029402 · Cited by 15
Advancing hypertension management: the role of zilebesiran as an siRNA therapeutic agent
Siddiqui, E., Siddiqui, A. H., Moeed, A., Laique, F., Najeeb, H., & Hasibuzzaman, M. A. (2024) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000002696 · Cited by 15
Proprotein convertase subtilisin/kexin type 9 inhibition as the next statin?
Rakipovski, G., Hovingh, G. K., & Nyberg, M. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000718 · Cited by 15
Cruz‐López, E. O., Ren, L., Uijl, E., Groningen, M. C. C., van Veghel, R., Garrelds, I. M., Domenig, O., Poglitsch, M., Zlatev, I., Rooney, T., et al. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15955 · Cited by 15
Drug Treatment of Hypercholesterolemia in Older Adults: Focus on Newer Agents
Stoll, F., Eidam, A., Michael, L., Bauer, J. M., & Haefeli, W. E. (2022) · Drugs & Aging · doi:10.1007/s40266-022-00928-z · Cited by 14
“Inclisiran did not induce an adverse immunological reaction as measured by platelet counts, lymphocyte, monocyte, neutrophil counts, tumor necrosis factor-α, interleukin-6, and antidrug antibodies [27].”
BackgroundPCSK9 Inhibition-Based Therapeutic Approaches: An Immunotherapy Perspective
Momtazi‐Borojeni, A. A., Pirro, M., Xu, S., & Sahebkar, A. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867328666211027125245 · Cited by 12
Luo, J., Liao, W., Wang, X., Xu, R., Li, W., Li, W., Liu, K., Huang, K., Ma, Y., Wang, T., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-062046 · Cited by 13
Personalized Medicine in Lipid-Modifying Therapy
Tomlinson, B., Lin, C.-H., Chan, P., & Lam, C. W. K. (2021) · Personalized Medicine · doi:10.2217/pme-2020-0110 · Cited by 12
Key inflammatory players for infarcted mass and cardiac remodeling after acute myocardial infarction
Fonseca, F. A. H., França, C. N., Fonseca, H. A. R., Serra, A. J., & Izar, M. C. D. O. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1609705 · Cited by 11
Cowart, K., Singleton, J., & Carris, N. W. (2023) · Clinical Therapeutics · doi:10.1016/j.clinthera.2023.06.011 · Cited by 11
Bellosta, S., Rossi, C., Alieva, A. S., Catapano, A. L., Corsini, A., & Baragetti, A. (2023) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07293-w · Cited by 10
“By contrast, inclisiran did not affect liver or kidney functions, creatine kinase, high-sensitivity C-reactive protein, or platelet levels [66] and rarely caused symptoms of immune system activation [67].”
BackgroundJeon, J. Y., Ayyar, V. S., Ouchi, S., Fabbrini, E., Koshkina, A., Prusakiewicz, J. J., Dallas, J., Yang, T., Jian, W., Kang, L., et al. (2024) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.6174 · Cited by 10
Insights from ORION studies: focus on inclisiran safety
Catapano, A. L., Pirillo, A., & Norata, G. D. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvaa139 · Cited by 10
An update on inclisiran for the treatment of elevated LDL cholesterol
Barkas, F., & Ray, K. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2337253 · Cited by 9
“Results from the analysis revealed that after 180 days of treat-ment, there were no significant changes in platelet counts or immune cell levels observed across all dosing groups compared to placebo [54].”
BackgroundInfluentialSelf-citationExploring neutrophils as therapeutic targets in cardiometabolic diseases
Albiero, M., & Baragetti, A. (2025) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2024.12.003 · Cited by 9
The contribution of extracellular RNA and its derived biomaterials in disease management
Yu, W. D., Wang, Z., Qin, Z., Wan, Q., Li, Y., Tay, F. R., Wang, C., Zhang, T., & Niu, L. (2024) · BMEMat · doi:10.1002/bmm2.12127 · Cited by 9
Bellosta, S., & Corsini, A. (2024) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2024.2402493 · Cited by 8
“This increases LDL-C receptor recycling and expression on the outside of the hepatocyte membrane, thus facilitating LDL uptake and reducing LDL-C levels [62,63].”
The Use of Biomarkers in Pharmacovigilance: A Systematic Review of the Literature
Salas, M., Gossell‐Williams, M., Yalamanchili, P., Dhingra, S., Malikova, M. A., Aimer, O., & Junaid, T. (2023) · Biomarker Insights · doi:10.1177/11772719231164528 · Cited by 7
“SAfETY 17,18,20,21,23,25,26,29,30,33,34 infections without compromising patient recovery.”
BackgroundMethodResultInfluentialMaliha, M., Satish, V., Kumar, S. S., Chi, K. Y., Shama, N., Kharawala, A., Duarte, G., Li, W., Purkayastha, S., Mangeshkar, S., et al. (2025) · Healthcare · doi:10.3390/healthcare13020141 · Cited by 6
“However, recent studies indicate that Inclisiran does not have a significant effect on immune cells, including leukocytes, monocytes, and neutrophils, as well as inflammatory biomarkers [34].”
Satyam, S. M., El-Tanani, M., Patni, M. A., Rehman, A., Irshad, S. M., Raheem, R., Junais, E., John, A. A., Rassal, R. Y., Kumari, R., et al. (2026) · BMC Cardiovascular Disorders · doi:10.1186/s12872-026-05515-3 · Cited by 5
“In ORION-1, approximately 5.5% of participants developed anti-drug antibodies (ADAs) against inclisiran [52].”
InfluentialTreatment of heterozygous familial hypercholesterolemia: what does the future hold?
Polychronopoulos, G., & Τζιόμαλος, Κ. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2020.1839417 · Cited by 5
Small Interfering Ribonucleic Acid as Lipid-Lowering Therapy: Inclisiran in Focus
Rakočević, J., Dobric, M. R., Vučić, R. M., Furtula, M., Zaletel, I. V., Milutinović, K., Ilijevski, A., Labudović‐Borović, M., Tomasevic, M. V., & Bajčetić, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24066012 · Cited by 5
“There were no changes in other proinflammatory markers, such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α), with any of inclisiran’s explored dosing regimens [28].”
BackgroundLiu, C.-L., Yang, M.-Q., Yang, M., Liu, Y.-R., Song, Z., Zhang, X., Yang, X.-J., & Zhao, Y.-T. (2023) · Analytical Biochemistry · doi:10.1016/j.ab.2023.115184 · Cited by 5
Antisense Oligonucleotides in Dyslipidemia Management: A Review of Clinical Trials
Ogieuhi, I. J., Callender, K., Odukudu, G.-D. O., Obi, E. S., Muzofa, K., Babalola, A. E., Ugiomoh, O. M.-A., Umenzeakor, K. H., Akingbola, A., Ayoson, C. O., et al. (2024) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-024-00682-w · Cited by 5
Ballman, K. K., Peek, V. L., Sloan, J. H., Li, J., Konrad, R. J., & Wen, Y. (2024) · The AAPS Journal · doi:10.1208/s12248-024-00914-w · Cited by 4
Marta, B., Białecka, M. A., Machoy‐Mokrzyńska, A., Malinowski, D., & Rać, M. E. (2025) · Archives of Medical Science · doi:10.5114/aoms/201446 · Cited by 6
Targeting PCSK9 beyond the liver: evidence from experimental and clinical studies
Dalt, L. D., Baragetti, A., & Norata, G. D. (2025) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2025.2482545 · Cited by 4
“Also, these two options did not lead to significant reduction in the plasma levels of markers of inflammation such as interleukin 6 (IL-6) and tumor necrosis factor-α (TNF-α) [109,112] (Table 2).”
Karsten, C., Grannas, K., Bergman, O., Movérare, R., Roforth, M. M., Willrich, M. A. V., Snyder, M. R., & Yang, Y. K. (2024) · The AAPS Journal · doi:10.1208/s12248-024-00953-3 · Cited by 3
“The safety monitoring of nucleotide-based therapeutics such as the mRNA vaccines were primarily carried out by cytokine responses (42).”
Deaney, C., Donaldson, M., & Meskauskiene, A. (2025) · Clinical Medicine Insights Cardiology · doi:10.1177/11795468251337425 · Cited by 4
FISIOPATOLOGIA E TRATAMENTOS ATUALMENTE DISPONÍVEIS PARA DISLIPIDEMIA
Almeida, A. B., Pontes, B. B., Gioia, L. N., & Rangel, V. (2023) · EPITAYA eBooks · doi:10.47879/ed.ep.2023809p32 · Cited by 5
PCSK9 siRNA INHIBITOR INCLISIRAN AS A TREATMENT OPTION IN HYPERCHOLESTEROLEMIA: A BRIEF REVIEW
Kılıç, M. E. (2023) · TURKISH MEDICAL STUDENT JOURNAL · doi:10.4274/tmsj.galenos.2023.2023-5-1 · Cited by 3
Novel therapeutic agents for cardiometabolic risk mitigation in heart transplant recipients
Gorrai, A., FARR, M. A., O’Hara, P. J., Beaini, H., HENDREN, N. S., Wrobel, C. A., Hardin, E. A., McGuire, D. K., Khera, A., Wang, T. J., et al. (2024) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2024.12.006 · Cited by 3
Chen, Y., Li, S., Wang, M., Wu, M., du, Z.-C., & Wei, L. (2024) · Journal of College of Physicians And Surgeons Pakistan · doi:10.29271/jcpsp.2024.09.1090 · Cited by 2
Pharmaceutical perspectives on oligonucleotide therapeutics and delivery systems
Staller, D. W., Gawargi, F. I., Panigrahi, S. S., Mishra, P. K., & Mahato, R. I. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100065 · Cited by 1
Update on Inclisiran for Treatment of Hypercholesterolemia
Mikhail, N. E. (2020) · Journal of Diabetes Research Review & Reports · doi:10.47363/jdrr/2020(2)106 · Cited by 2
Inclisiran: new era of lipid-lowering therapy?
Beneš, J. (2023) · Cor et Vasa · doi:10.33678/cor.2022.043 · Cited by 1
APPARATUS FOR $beta$ PARTICLES BACKSCATTERING ANALYSIS IN MIXTURES OF CLOSE ATOMIC NUMBERS.
Parus, J. L., Kowalski, Z. S., & Ney, W. (1968) · OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information)
Angiotensinogen suppression: a promising approach
(2021) · Hypertension News · doi:10.30824/2112-8
Research Progress of Inclisiran
王, 玉. (2022) · Advances in Clinical Medicine · doi:10.12677/acm.2022.1281061
Inclisiran — lipid-lowering drug using RNA therapy. Hypolipidemic potential
Sumarokov, A. M. (2022) · Russian Cardiology Bulletin · doi:10.17116/cardiobulletin20221704132 · Cited by 1
Brandts, J., & Ray, K. K. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00021-2
Self-citationCARDIOLOGIA EM FOCO: PREVENÇÃO, DIAGNÓSTICO E TRATAMENTOS ATUAIS
Almeida, A. B., & Horevicht, C. M. (2023) · EPITAYA eBooks · doi:10.47879/ed.ep.2023809
Von Kräutern zu Pillen, Biologics und Nukleinsäuren
Lüscher, T. F., von Eckardstein, A., Beer, J. H., Räber, L., Sudano, I., Nanchen, D., Mueller, C. E., Mach, F., & Landmesser, U. (2022) · Cardiovascular Medicine · doi:10.4414/cvm.2022.02258
Self-citationRNA-Based Therapies for Hypercholesterolemia and Coronary Artery Disease
Mendoza, M. J. L., Figueroa, N. C., Mena, M. J. V., Ulloa, A., Vindas, J. J., & Estrada, M. A. S. (2026) · Cureus · doi:10.7759/cureus.103877
“The therapy’s infrequent dosing schedule also represents an important advantage, as improved adherence addresses a persistent barrier to achieving optimal LDL-C control with current therapies [19,36].”
Evidence‐Based Recommendations on the Use of Inclisiran in Patients With Chronic Kidney Disease
Sharma, S., Kalra, S., Sahay, M., Kapoor, N., Nagendra, L., Verma, H., Sharma, N., Verma, M., RAJU, S. B., & Tang, S. C. W. (2026) · Nephrology · doi:10.1111/nep.70206
“For transplant candidates, it is advisable to postpone initiation of Inclisiran until the hepatitis B vaccination is completed, due to theoretical concerns that PCSK9 inhibitors might modulate patients' immune responses [28, 29].”
Inclisiran—will it fulfill its promise?
Zadeh, S. S. T., Fogacci, F., & Hadaegh, F. (2026) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2026.104848
Matteucci, A., Bonanni, M., Fusco, S. A. D., Aiello, A., Aquilani, S., Fedele, S., Nardi, F., & Colivicchi, F. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.09.012
PCSK9 in the Immunometabolism of Type 2 Diabetes
Villari, P., & Labate, A. M. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27219723
Metadata
- Authors
- Landmesser, U., Haghikia, A., Leiter, L. A., Wright, R. S., Kallend, D., Wijngaard, P., Stoekenbroek, R., Kastelein, J. J., & Ray, K. K.
- Affiliations
- German Centre for Cardiovascular Research (DE)
- St. Michael's Hospital (CA)
- Mayo Clinic (US)
- The Medicines Company, 8001 Zurich, Switzerland
- Medicines Company (United States) (US)
- Amsterdam UMC Location University of Amsterdam (NL)
- Imperial College London (GB)
- Corresponding author
- Landmesser, Ulf
- Haghikia, Arash
- ORCID
- Venue
- Cardiovascular Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-04-03
- Volume
- 117
- Issue
- 1
- Pages
- 284-291
- ISSN
- 0008-6363 (ISSN-L)
- 1755-3245
- OpenAlex
- W3014622477
- Semantic Scholar
- eec192fa6580eb33c83effd381be88fd3b0dfac7
- Cited by
- 83
- References
- 19
- Citations by year
- 2026: 6 · 2025: 7 · 2024: 15 · 2023: 17 · 2022: 16 · 2021: 14 · 2020: 7
- FWCI
- 12.34
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Cardiovascular Research (publishedVersion)
- PubMed (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Spiral (Imperial College London) (submittedVersion)
- Funders
- Kowa and the Medicines Company
- AstraZeneca
- The Medicines Company
- CIVI Biotechnology
- Corvidia
- CSL Behring
- Daiichi Sankyo
- Draupnir
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Keywords
- inclisiran, immunogenicity, anti-drug antibodies, platelet count, lymphocytes, monocytes, interleukin-6, TNF-α, LDL cholesterol lowering, cardiovascular disease, immunological biomarkers, dosing regimen, pharmacovigilance, thrombocytopenia
- MeSH terms
- RNAi Therapeutics, Proprotein Convertase 9, Antibodies, Blood Platelets, Double-Blind Method, Humans, Leukocytes, Cholesterol, LDL, Time Factors, Tumor Necrosis Factor-alpha, Biomarkers, Down-Regulation, Interleukin-6, Treatment Outcome, RNA, Small Interfering, Dyslipidemias
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.